CL2019000017A1 - Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble. - Google Patents

Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble.

Info

Publication number
CL2019000017A1
CL2019000017A1 CL2019000017A CL2019000017A CL2019000017A1 CL 2019000017 A1 CL2019000017 A1 CL 2019000017A1 CL 2019000017 A CL2019000017 A CL 2019000017A CL 2019000017 A CL2019000017 A CL 2019000017A CL 2019000017 A1 CL2019000017 A1 CL 2019000017A1
Authority
CL
Chile
Prior art keywords
preparation
compound
guanylate cyclase
soluble guanylate
novel processes
Prior art date
Application number
CL2019000017A
Other languages
English (en)
Inventor
Song Xue
Vishnu Vardhan Reddy Karnati
Robert C Livingston
Wayne C Schairer
Timothy Claude Barden
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of CL2019000017A1 publication Critical patent/CL2019000017A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE RELACIONA CON PROCESOS NOVEDOSOS PARA LA PREPARACIÓN DE COMPUESTOS ÚTILES COMO ESTIMULADORES DE GUANILATO CICLASA SOLUBLE (SGC, POR SUS SIGLAS EN INGLÉS). ESTOS PROCESOS PUEDEN PREPARARSE A GRAN ESCALA Y PRODUCIR 3-(2-PIRIMIDINIL)PIRAZOLES ESTABLES DE LA FÓRMULA (I), QUE INCLUYEN EL COMPUESTO (I), EL COMPUESTO (IA) Y EL COMPUESTO (IB), EN ALTA PUREZA Y RENDIMIENTOS. LA PRESENTE INVENCIÓN TIENE LA VENTAJA ADICIONAL DE CONDICIONES DE REACCIÓN FÁCILES, SUSCEPTIBLE A ESCALARSE PARA FABRICACIÓN A GRAN ESCALA. LA DESCRIPCIÓN PROPORCIONA, ADEMÁS, INTERMEDIARIOS NOVEDOSOS ÚTILES PARA LA PREPARACIÓN DE DICHOS COMPUESTOS.
CL2019000017A 2016-07-07 2019-01-04 Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble. CL2019000017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662359430P 2016-07-07 2016-07-07

Publications (1)

Publication Number Publication Date
CL2019000017A1 true CL2019000017A1 (es) 2019-05-03

Family

ID=59351140

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000017A CL2019000017A1 (es) 2016-07-07 2019-01-04 Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble.

Country Status (17)

Country Link
US (2) US11834444B2 (es)
EP (1) EP3481821B1 (es)
JP (1) JP7054395B2 (es)
KR (1) KR102513357B1 (es)
CN (1) CN109563086B (es)
AU (1) AU2017292811B2 (es)
BR (1) BR112019000292A2 (es)
CA (1) CA3029376A1 (es)
CL (1) CL2019000017A1 (es)
EA (1) EA201990236A1 (es)
ES (1) ES2962829T3 (es)
IL (1) IL263994B (es)
JO (1) JOP20180126A1 (es)
MA (1) MA45593A (es)
MX (1) MX2019000138A (es)
SG (2) SG11201900125PA (es)
WO (1) WO2018009602A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900096QA (en) * 2016-07-07 2019-02-27 Ironwood Pharmaceuticals Inc Novel processes for preparation of soluble guanylate cyclase stimulators
IL314714A (en) 2018-01-10 2024-10-01 Cyclerion Therapeutics Inc PROCESSES AND INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF SOLUBLE GIONLIGHT CYCLAS FANS
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101955439A (zh) * 2009-07-14 2011-01-26 华东理工大学 一种α-取代-2-氨基乙酰胺的拆分方法
AR088020A1 (es) 2010-06-30 2014-05-07 Ironwood Pharmaceuticals Inc Compuestos heterociclicos como estimuladores de sgc
MX336966B (es) * 2011-01-13 2016-02-08 Novartis Ag Novedosos derivados y su uso en el tratamiento de transtornos neurologicos.
CN104066731B (zh) * 2011-12-27 2016-06-15 铁木医药有限公司 可用作sgc刺激剂的2-苄基、3-(嘧啶-2-基)取代的吡唑类
KR102362835B1 (ko) 2013-03-15 2022-02-14 사이클리온 테라퓨틱스, 인크. ｓＧＣ 자극인자
MX2017003516A (es) 2014-09-17 2017-07-28 Ironwood Pharmaceuticals Inc Derivados de pirazol como estimuladores de guanilato ciclasa soluble (sgc).
CN116637076A (zh) 2015-11-30 2023-08-25 赛克里翁治疗有限公司 包含sGC刺激剂的固体分散体
SG11201900096QA (en) * 2016-07-07 2019-02-27 Ironwood Pharmaceuticals Inc Novel processes for preparation of soluble guanylate cyclase stimulators
US10889577B2 (en) 2016-07-07 2021-01-12 Cyclerion Therapeutics, Inc. Solid forms of an sGC stimulator

Also Published As

Publication number Publication date
MX2019000138A (es) 2019-06-10
AU2017292811A1 (en) 2019-02-07
IL263994A (en) 2019-01-31
AU2017292811B2 (en) 2021-10-21
WO2018009602A3 (en) 2018-03-15
WO2018009602A2 (en) 2018-01-11
US20240199595A1 (en) 2024-06-20
EP3481821A2 (en) 2019-05-15
ES2962829T3 (es) 2024-03-21
EP3481821C0 (en) 2023-09-06
EP3481821B1 (en) 2023-09-06
SG11201900125PA (en) 2019-02-27
IL263994B (en) 2021-10-31
US20210284632A1 (en) 2021-09-16
SG10202100168XA (en) 2021-02-25
US11834444B2 (en) 2023-12-05
JP2019524712A (ja) 2019-09-05
EA201990236A1 (ru) 2019-08-30
KR20190025987A (ko) 2019-03-12
BR112019000292A2 (pt) 2019-04-16
CN109563086A (zh) 2019-04-02
JP7054395B2 (ja) 2022-04-13
CA3029376A1 (en) 2018-01-11
KR102513357B1 (ko) 2023-03-24
JOP20180126A1 (ar) 2019-01-30
CN109563086B (zh) 2023-05-23
MA45593A (fr) 2019-05-15

Similar Documents

Publication Publication Date Title
CL2019000017A1 (es) Procesos novedosos para la preparación de estimuladores de guanilato ciclasa soluble.
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
CL2019000016A1 (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
BR112017024235A2 (pt) processo para produção de um agente quelante, mistura de compostos, solução aquosa, e, uso de uma mistura ou de uma solução aquosa.
EA201890752A1 (ru) Способ получения противогрибковых соединений
AR094948A1 (es) Preparación de haloalcoxiarilhidracinas y los intermediarios a partir de los mismos
CU24341B1 (es) Compuestos y composiciones orgánicas inhibidores del ácido graso sintetasa (fasn) útiles para el tratamiento del cáncer, infecciones virales, obesidad y diabetes
AR107547A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
BR112017005218A2 (pt) mistura de compostos, processo para fabricar uma mistura, formulação aquosa, e, uso de misturas de compostos.
CL2020001814A1 (es) Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble.
MX2015017536A (es) Alquilacion con un alquil sulfonato de fluoroalquilo.
BR112018001255A2 (pt) composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos
PE20170212A1 (es) Composicion reactiva basada en bicarbonato de sodio y procedimiento para su produccion
CL2015001289A1 (es) Nuevos derivados de 1,4-ditiina sustituida y su uso como fungicidas
CL2013000601A1 (es) Mezcla estable que comprende particulas modificadas en superficie que se obtienen por la reaccion de particulas de oxido metalico, donde dicho oxido usado es oxido de un metal con al menos un compuesto de formula i y al menos un solvente; proceso para tratar particulas; uso de particulas; y proceso de preparacion de particulas.
BR112015007821A2 (pt) processo para a preparação de voriconazol e análogos do mesmo
BR112017013266A2 (pt) processo para preparação de um composto, composto, e, usos de um composto e de uma dispersão.
MX2017007385A (es) Estabilizacion de nanoparticulas hexagonales de nitruro de boro.
AR082775A1 (es) Formulaciones de fumarato
AR094706A1 (es) Proceso para producir compuesto de piridazinona y producción de sus intermediarios
BR112017028433A2 (pt) ?processo para preparação de um derivado de furfural?
AR107672A1 (es) Proceso para la fabricación de derivados de 3-piperazin-1-il-propilamina
EA202091664A1 (ru) Новые способы и промежуточные соединения для получения стимуляторов растворимой гуанилатциклазы
AR107109A1 (es) Proceso para elaborar crotonilaminopiridinas